Todurga, Zeynep GizemGunduz, OzgurKaradag, Cetin HakanUlugol, Ahmet2024-06-122024-06-1220161601-5215https://doi.org/10.1017/neu.2016.16https://hdl.handle.net/20.500.14551/19485Background: For centuries, cannabinoids have been known to be effective in pain states. Itch and pain are two sensations sharing a lot in common. Objective: The goal of this research was to observe whether the cannabinoid agonist WIN 55,212-2 reduces serotonin-induced scratching behaviour and whether neurotoxic destruction of descending serotonergic and noradrenergic pathways mediate the antipruritic effect of WIN 55,212-2. Material and methods: Scratching behaviour was induced by intradermal injection of serotonin (50 mu g/50 mu l/mouse) to Balb/c mice. The neurotoxins 5,7-dihydroxytryptamine (5,7-DHT, 50 mu g/mouse) and 6-hydroxydopamine (6-OHDA, 20 mu g/mouse) are applied intrathecally to deplete serotonin and noradrenaline in the spinal cord. WIN 55,212-2 (1, 3, 10 mg/kg, i.p.) dose-dependently attenuated serotonin-induced scratches. Neurotoxic destruction of neither the serotonergic nor the noradrenergic systems by 5,7-DHT and 6-OHDA, respectively, had any effect on the antipruritic action of WIN 55,212-2. Conclusion: Our findings indicate that cannabinoids dose-dependently reduce serotonin-induced scratching behaviour and neurotoxic destruction of descending inhibitory pathways does not mediate this antipruritic effect.en10.1017/neu.2016.16info:eu-repo/semantics/closedAccessCannabinoid SystemDescending InhibitionWIN 55,212-2PruritusSpinal 5-Ht7 ReceptorsItch-Related ResponsesEndocannabinoid ModulationTherapeutic TargetMicePathwaysPainActivationCb1AntinociceptionArticle286321326Q3WOS:0003878238000032-s2.0-8500630724227805543Q2